NASDAQ:SRNE
Delisted
Sorrento Therapeutics Stock News
$0.307
+0 (+0%)
At Close: Feb 23, 2023
Sorrento Has Potential To Deliver Multiple Best-In-Class Products
07:09pm, Wednesday, 02'nd Nov 2022 Benzinga
Cantor Fitzgerald initiated coverage on Sorrento Therapeutics Inc (NASDAQ: SRNE) with an Overweight rating and a price target of $5.
The analyst says Sorrento has the potential to deliver multipl
Benzinga's Top Ratings Upgrades, Downgrades For November 2, 2022
02:06pm, Wednesday, 02'nd Nov 2022 Benzinga
Upgrades
According to Evercore ISI Group, the prior rating for BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) was changed from In-Line to Outperform. In the third quarter, BioCryst Pharmaceuticals showed
Alnylam Pharmaceuticals (ALNY) Reports Q3 Loss, Misses Revenue Estimates
01:15pm, Thursday, 27'th Oct 2022 Zacks Investment Research
Alnylam (ALNY) delivered earnings and revenue surprises of -78.49% and 7.36%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Why Sorrento Therapeutics Stock Is on the Rise Today
04:22pm, Thursday, 20'th Oct 2022 The Motley Fool
The drugmaker's stock is moving upward today in sympathy with the broader biopharmaceutical industry.
7 of the Best Contrarian Stocks to Buy When Investors Are Fearful
12:23pm, Thursday, 20'th Oct 2022
Contrarian investing is not easy, and it certainly takes a great deal of courage. Forbes defines contrarian investing as “holding a viewpoint on the market that is out of favor, and then doing the n
Why Sorrento Therapeutics Stock Is on the Rise Today
12:22pm, Thursday, 20'th Oct 2022
The drugmaker's stock is moving upward today in sympathy with the broader biopharmaceutical industry.
SAN DIEGO, Oct. 14, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced publication in the Cell Press journal Med of data detailing work relating to the
Sorrento Therapeutics to Participate in Key Opinion Leader Panel Discussion on “New Horizons for the Treatment of Non-small Cell Lung Cancer”
01:00pm, Thursday, 06'th Oct 2022 GlobeNewswire Inc.
Panel to Discuss Unmet Need in Non-small Cell Lung Cancer and the Potential for Abivertinib, a Novel Third Generation epidermal growth factor receptor / Bruton’s tyrosine kinase (EGFR/BTK) Inhibitor
Why Sorrento Therapeutics' Shares Tumbled 23.4% in September
10:25pm, Tuesday, 04'th Oct 2022 The Motley Fool
Sorrento's financials are not helping it in the current down market.
Why Sorrento Therapeutics' Shares Tumbled 23.4% in September
06:25pm, Tuesday, 04'th Oct 2022
Sorrento's financials are not helping it in the current down market.
Morphic Holding, Inc. (MORF) Moves 7.3% Higher: Will This Strength Last?
02:15pm, Thursday, 29'th Sep 2022 Zacks Investment Research
Morphic Holding, Inc. (MORF) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the
Sorrento Announces the Publication in the Nature Journal Scientific Reports the Details of the Discovery of SARS-CoV-2 Neutralizing Antibodies from the G-MAB Library
07:34pm, Thursday, 15'th Sep 2022 GlobeNewswire Inc.
SAN DIEGO, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced publication of peer-reviewed data detailing the discovery and preclinical profil
10 Top Penny Stocks With Unusual Options Activity This Week
07:27pm, Thursday, 08'th Sep 2022 PennyStocks
Penny stocks to watch today with unusual options action.
The post 10 Top Penny Stocks With Unusual Options Activity This Week appeared first on Penny Stocks to Buy, Picks, News and Information | Penny
10 Top Penny Stocks With Unusual Options Activity This Week
03:27pm, Thursday, 08'th Sep 2022
Penny stocks to watch today with unusual options action. The post 10 Top Penny Stocks With Unusual Options Activity This Week appeared first on Penny Stocks to Buy, Picks, News and Information | Penny
Sorrento Therapeutics to Participate in Morgan Stanley 20th Annual Global Healthcare Conference September 12-14
09:00am, Thursday, 08'th Sep 2022
SAN DIEGO, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced that Henry Ji, Ph.D., Chairman, President and Chief Executive Officer, and memb
